End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
2.04
CNY
|
-2.39%
|
|
-5.12%
|
-18.73%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,155
|
6,660
|
7,034
|
6,397
|
5,583
|
5,517
|
Enterprise Value (EV)
1 |
7,970
|
8,026
|
7,491
|
6,459
|
5,750
|
5,482
|
P/E ratio
|
48.9
x
|
-2.5
x
|
17.6
x
|
142
x
|
-19.2
x
|
45.9
x
|
Yield
|
0.43%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.12
x
|
1.32
x
|
2.3
x
|
2.03
x
|
1.8
x
|
2.1
x
|
EV / Revenue
|
1.45
x
|
1.59
x
|
2.45
x
|
2.05
x
|
1.85
x
|
2.09
x
|
EV / EBITDA
|
11.6
x
|
13.5
x
|
4,078
x
|
25.5
x
|
26.8
x
|
19.9
x
|
EV / FCF
|
13.1
x
|
60.8
x
|
66.4
x
|
24.8
x
|
112
x
|
54.4
x
|
FCF Yield
|
7.62%
|
1.65%
|
1.51%
|
4.03%
|
0.89%
|
1.84%
|
Price to Book
|
1.42
x
|
4.38
x
|
3.81
x
|
3.38
x
|
3.42
x
|
3.32
x
|
Nbr of stocks (in thousands)
|
2,198,123
|
2,198,123
|
2,198,123
|
2,198,123
|
2,198,123
|
2,198,123
|
Reference price
2 |
2.800
|
3.030
|
3.200
|
2.910
|
2.540
|
2.510
|
Announcement Date
|
4/23/19
|
4/27/20
|
4/28/21
|
4/25/22
|
4/23/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5,481
|
5,054
|
3,055
|
3,145
|
3,108
|
2,626
|
EBITDA
1 |
684.9
|
595
|
1.837
|
253.2
|
214.5
|
275.5
|
EBIT
1 |
503.3
|
416.3
|
-144.7
|
115.7
|
85.61
|
172
|
Operating Margin
|
9.18%
|
8.24%
|
-4.74%
|
3.68%
|
2.75%
|
6.55%
|
Earnings before Tax (EBT)
1 |
178.9
|
-2,604
|
565.1
|
85.97
|
-269.7
|
176.8
|
Net income
1 |
125.9
|
-2,662
|
400
|
45.04
|
-291.3
|
120.3
|
Net margin
|
2.3%
|
-52.67%
|
13.1%
|
1.43%
|
-9.37%
|
4.58%
|
EPS
2 |
0.0573
|
-1.211
|
0.1820
|
0.0205
|
-0.1325
|
0.0547
|
Free Cash Flow
1 |
607.1
|
132.1
|
112.8
|
260.4
|
51.24
|
100.7
|
FCF margin
|
11.08%
|
2.61%
|
3.69%
|
8.28%
|
1.65%
|
3.83%
|
FCF Conversion (EBITDA)
|
88.64%
|
22.2%
|
6,142.39%
|
102.82%
|
23.89%
|
36.54%
|
FCF Conversion (Net income)
|
482.21%
|
-
|
28.2%
|
578.03%
|
-
|
83.67%
|
Dividend per Share
2 |
0.0120
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/23/19
|
4/27/20
|
4/28/21
|
4/25/22
|
4/23/23
|
4/19/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,815
|
1,366
|
457
|
62.4
|
167
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
35.6
|
Leverage (Debt/EBITDA)
|
2.65
x
|
2.296
x
|
248.8
x
|
0.2465
x
|
0.777
x
|
-
|
Free Cash Flow
1 |
607
|
132
|
113
|
260
|
51.2
|
101
|
ROE (net income / shareholders' equity)
|
2.98%
|
-88.8%
|
23.2%
|
2.75%
|
-15.7%
|
7.54%
|
ROA (Net income/ Total Assets)
|
3.39%
|
3.28%
|
-1.66%
|
1.57%
|
1.22%
|
2.97%
|
Assets
1 |
3,710
|
-81,261
|
-24,162
|
2,869
|
-23,874
|
4,045
|
Book Value Per Share
2 |
1.970
|
0.6900
|
0.8400
|
0.8600
|
0.7400
|
0.7600
|
Cash Flow per Share
2 |
0.5900
|
0.6000
|
0.4100
|
0.6800
|
0.5600
|
0.3200
|
Capex
1 |
104
|
48.4
|
43.7
|
34.5
|
33
|
29.6
|
Capex / Sales
|
1.9%
|
0.96%
|
1.43%
|
1.1%
|
1.06%
|
1.13%
|
Announcement Date
|
4/23/19
|
4/27/20
|
4/28/21
|
4/25/22
|
4/23/23
|
4/19/24
|
|
1st Jan change
|
Capi.
|
---|
| -18.73% | 655M | | +18.71% | 44.35B | | +19.44% | 15.08B | | +19.49% | 14.37B | | +57.58% | 13.06B | | -0.05% | 6.79B | | -9.70% | 6.75B | | -8.87% | 5.73B | | +13.66% | 5.64B | | +4.00% | 4.66B |
Generic Pharmaceuticals
|